

Angela Loyse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1366599/publications.pdf>

Version: 2024-02-01

46
papers

4,912
citations

236925

25
h-index

214800

47
g-index

48
all docs

48
docs citations

48
times ranked

3598
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. <i>New England Journal of Medicine</i> , 2022, 386, 1109-1120.	27.0	119
2	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. <i>Clinical Infectious Diseases</i> , 2021, 72, 1268-1278.	5.8	51
3	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 16-18.	9.1	18
4	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab066.	0.9	6
5	Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy- Naïve and Experienced Patients in Sub-Saharan Africa. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab397.	0.9	9
6	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1266.	0.9	9
7	Cryptococcal meningoencephalitis: time for action. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e259-e271.	9.1	29
8	One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. <i>Clinical Infectious Diseases</i> , 2020, 70, 521-524.	5.8	13
9	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 26-29.	5.8	13
10	A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK. <i>Journal of Infection</i> , 2020, 80, 38-41.	3.3	8
11	Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme. <i>International Journal of Infectious Diseases</i> , 2020, 95, 459-461.	3.3	10
12	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa489.	0.9	12
13	New Insights Into <i>Cryptococcus</i> Spp. Biology and Cryptococcal Meningitis. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 81.	4.2	13
14	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2019, 69, 588-595.	5.8	18
15	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019, 9, e026288.	1.9	6
16	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e143-e147.	9.1	63
17	Long term mortality and disability in Cryptococcal Meningitis: a systematic literature review.. <i>Clinical Infectious Diseases</i> , 2018, 66, 1122-1132.	5.8	53
18	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. <i>New England Journal of Medicine</i> , 2018, 378, 1004-1017.	27.0	296

#	ARTICLE	IF	CITATIONS
19	Effect of oral fluconazole 1200mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis. <i>Aids</i> , 2018, 32, 2259-2261.	2.2	4
20	AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> , 2018, 19, 649.	1.6	41
21	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. <i>MBio</i> , 2018, 9, .	4.1	5
22	Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. <i>Frontiers in Microbiology</i> , 2018, 9, 409.	3.5	46
23	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 873-881.	9.1	1,559
24	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008–2014. <i>Journal of Infection</i> , 2017, 74, 260-271.	3.3	15
25	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	37
26	Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. <i>Nature Reviews Neurology</i> , 2017, 13, 13-24.	10.1	344
27	Cryptococcal meningitis: A neglected NTD?. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005575.	3.0	47
28	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003847.	3.0	94
29	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7224-7231.	3.2	99
30	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. <i>Clinical Infectious Diseases</i> , 2014, 58, 736-745.	5.8	299
31	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 493-500.	5.8	10
32	Access to antifungal medicines in resource-poor countries – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 371.	9.1	4
33	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2000-2008.	8.2	130
34	Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 629-637.	9.1	151
35	Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2435-2444.	3.0	121
36	Early Clinical and Subclinical Visual Evoked Potential and Humphrey's Visual Field Defects in Cryptococcal Meningitis. <i>PLoS ONE</i> , 2012, 7, e52895.	2.5	20

#	ARTICLE	IF	CITATIONS
37	Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2012, 54, 121-128.	5.8	127
38	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1815-1820.	3.0	80
39	Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. <i>Aids</i> , 2010, 24, 405-410.	2.2	64
40	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 702-709.	5.8	201
41	Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis: A Prospective Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 130-134.	2.1	162
42	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. <i>Aids</i> , 2009, 23, 1182-1183.	2.2	83
43	Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. <i>Aids</i> , 2009, 23, 701-706.	2.2	168
44	High-Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV-Infected Patients: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 123-130.	5.8	238
45	Reply to Pasqualotto. <i>Clinical Infectious Diseases</i> , 2008, 47, 1110-1111.	5.8	2
46	<i>Pseudomonas stutzeri</i> pneumonia in an HIV seropositive patient. <i>Journal of Infection</i> , 2006, 53, 75-76.	3.3	13